Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesDestiny Pharma PLC

Destiny Pharma PLC

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None GBX 0.00(0%)
Last update at 2024-09-11T12:00:33.566658Z
Market Cap
73.36M

Momentum Score

…

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product, which is in preclinical stage for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Research/Biofilms that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. In addition, the company is involved in the development of XF drugs for the treatment of respiratory, dermal, oral and ocular infections. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; Sebela Pharmaceuticals; the University of Southampton; Aston University; the University of Sheffield; National Biofilms Innovation Centre; National Institute of Allergy and Infectious Diseases; Cystic Fibrosis Foundation; Cardiff University; and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
25.00
Low
84.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
3.00
Dividend Yield
-
Revenue TTM
0.99M
Revenue Per Share
0.01
Gross Profit TTM
0.14M
Debt / Equity
-
ROE
-52.87%
Net Debt
-4.90M
ROCE
-101.97%
Diluted EPS TTM
-0.08

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -7.71M -6.27M -6.48M -5.52M -6.01M
Net income -6.50M -5.34M -5.41M -4.71M -5.17M
Selling general administrative 7.40M 6.02M 6.43M 5.69M 5.35M
Gross profit - - -4.50M -3.83M -
Reconciled depreciation 0.01M 0.01M 0.02M 0.02M 0.01M
Ebit -7.78M -6.29M -6.55M -5.58M -6.08M
Ebitda -7.76M -6.27M -6.54M -5.57M -6.07M
Depreciation and amortization 0.01M 0.01M 0.02M 0.02M 0.01M
Operating income -7.78M -6.29M -6.55M -5.58M -6.08M
Other operating expenses 7.78M 6.29M 6.55M 5.58M 6.08M
Interest expense 0.06M 0.02M 0.07M 0.06M 0.08M
Tax provision -1.21M -0.93M -1.07M -0.81M -0.84M
Interest income 0.06M 0.02M 0.07M 0.06M 0.08M
Net interest income 0.06M 0.02M 0.07M 0.06M 0.08M
Income tax expense -1.21M -0.93M -1.07M -0.81M -0.84M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 7.78M 6.29M 6.55M 5.58M 6.08M
Cost of revenue - - 4.50M 3.83M -
Total other income expense net 0.06M 0.02M 0.07M 0.06M 0.08M
Net income from continuing ops -6.50M -5.34M -5.41M -4.71M -5.17M
Net income applicable to common shares - -5.34M -5.41M -4.71M -5.17M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 8.80M 8.28M 13.70M 8.56M 13.06M
Intangible assets 2.26M 2.26M 2.26M - -
Other current assets - 1.34M 1.68M 1.04M 0.97M
Total liab 1.17M 0.77M 1.27M 0.80M 0.80M
Total stockholder equity 7.63M 7.51M 12.44M 7.76M 12.26M
Other current liab 1.00M 0.56M 0.54M 0.28M 0.40M
Common stock 0.73M 0.60M 0.60M 0.44M 0.44M
Capital stock 0.73M 0.60M 0.60M 0.44M 0.44M
Retained earnings -26.15M -20.18M -15.25M -9.98M -5.47M
Other assets - - 0.00M - -
Cash 4.90M 4.65M 9.74M 7.48M 7.06M
Total current liabilities 1.17M 0.77M 1.27M 0.80M 0.80M
Net debt -4.90M -4.65M -9.74M -7.48M -7.06M
Short term debt - - - - 5.00M
Other stockholder equity 33.04M 27.09M 27.09M 17.30M 17.36M
Property plant equipment 0.02M 0.04M 0.02M 0.03M 0.03M
Total current assets 6.51M 5.99M 11.42M 8.52M 13.03M
Net tangible assets 5.36M 5.25M 10.17M 7.76M 12.26M
Short term investments - - - - 5.00M
Net receivables 1.41M 0.99M 1.17M 0.91M 0.93M
Accounts payable 0.17M 0.22M 0.73M 0.51M 0.40M
Accumulated other comprehensive income - - - -0.09M -0.07M
Common stock total equity - - 0.60M 0.44M 0.44M
Non currrent assets other - - - 0.03M 0.03M
Non current assets total 2.29M 2.30M 2.28M 0.03M 0.03M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 0.06M -0.01M -2.19M 5.00M 5.00M
Change to liabilities 0.00M -0.49M 0.47M -0.00M 0.40M
Total cashflows from investing activities - -0.01M -2.19M 5.04M 0.06M
Total cash from financing activities 6.09M 0.01M 9.95M 0.01M 0.01M
Net income -7.71M -6.27M -6.48M -5.52M -6.01M
Change in cash 0.26M -5.10M 2.26M 0.42M -4.66M
Begin period cash flow 4.65M 9.74M 7.48M 7.06M 11.72M
End period cash flow 4.90M 4.65M 9.74M 7.48M 7.06M
Total cash from operating activities -5.89M -5.09M -5.49M -4.63M -4.72M
Issuance of capital stock 6.09M 0.01M 9.95M 0.01M 0.00M
Depreciation 0.01M 0.01M 0.02M 0.02M 0.01M
Other cashflows from investing activities - 0.02M 0.07M 0.06M 0.08M
Change to account receivables - 0.20M -0.38M -0.08M -0.02M
Sale purchase of stock - - 9.95M 0.01M -
Other cashflows from financing activities 0.06M -0.01M -2.19M 5.04M 0.06M
Change to netincome - 0.53M -0.19M 0.14M 0.05M
Capital expenditures 0.00M 0.03M 2.26M 0.02M 0.02M
Change in working capital 0.41M -0.30M 0.09M -0.08M 0.38M
Stock based compensation 0.53M 0.41M 0.14M 0.20M 0.74M
Other non cash items 0.86M -0.02M -0.07M -0.06M 0.16M
Free cash flow -5.89M -5.12M -7.76M -4.65M -4.74M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
GNS
Genus PLC		 18.00
0.78%		 2340.00 36.08 26.18 2.53 3.46 15.38
ONT
Oxford Nanopore Technologies Ltd		 10.60
4.93%		 225.60 - - 4.71 2.50 -8.89
OXB
Oxford BioMedica PLC		 5.00
0.95%		 532.00 - 208.33 4.05 7.60 308.96
AVCT
Avacta Group PLC		 -1.00
1.60%		 61.50 - - 2849.46 1929.84 -12.04

Profile*

Destiny Pharma PLC

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product, which is in preclinical stage for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Research/Biofilms that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. In addition, the company is involved in the development of XF drugs for the treatment of respiratory, dermal, oral and ocular infections. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; Sebela Pharmaceuticals; the University of Southampton; Aston University; the University of Sheffield; National Biofilms Innovation Centre; National Institute of Allergy and Infectious Diseases; Cystic Fibrosis Foundation; Cardiff University; and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.

Sussex Innovation Centre, Brighton, United Kingdom, BN1 9SB

44 1273 704440

https://www.destinypharma.com

24

Name Title Year Born
Mr. Neil Robert Clark CEO & Director 1963
Dr. William Guy Love Founder, Chief Scientific Officer & Director 1963
Mr. Shaun Claydon ACA CFO, Company Sec. & Director 1968
Dr. Stephanie Bewick Chief Bus. Officer NA
Dr. Yuri Martina M.B.A., M.D. Chief Medical Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

LIF
CAD 21.93
+8.08%
CRON
CAD 5.29
+7.30%
CIA
CAD 2.05
+6.77%
THX
CAD 0.97
+5.43%
OGC
CAD 37.98
+5.38%
GIL
CAD 46.87
-22.45%
IFOS
CAD 1.70
-20.56%
ITH
CAD 1.99
-18.65%
KEEL
CAD 2.41
-17.75%
TNZ
CAD 51.05
-17.39%

Equity Sectors*

  • Basic Materials

    -2.08%

  • Communication Services

    +0.74%

  • Consumer Cyclical

    -2.22%

  • Consumer Defensive

    -0.50%

  • Energy

    -2.12%

  • Financial Services

    -1.76%

  • Healthcare

    -1.14%

  • Industrials

    -3.05%

  • Real Estate

    -0.47%

  • Technology

    -3.49%

  • Utilities

    -1.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…